Please try another search
ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized vesicles secreted by stem cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.
Name | Age | Since | Title |
---|---|---|---|
Iain Gladstone Ross | 69 | 2021 | Executive Chairman |
Michael John Owen | 72 | 2015 | Independent Non-Executive Director |
Martin Charles Walton | 58 | 2022 | Independent Non-Executive Director |
Barbara Regina Staehelin | 60 | 2021 | Senior Independent Non-Executive Director |
Giuseppe Battaglia | - | 2023 | Member of Scientific Advisory Board |
Kenneth W. Witwer | - | 2023 | Member of Scientific Advisory Board |
Stefano Pluchino | - | 2021 | Chair of the Scientific Advisory Board |
Bernd Giebel | - | 2023 | Member of Scientific Advisory Board |
Edit I. Buzas | - | 2023 | Member of Scientific Advisory Board |
John Michael Hawkins | 56 | 2021 | Company Secretary, CFO & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review